Verona Pharma to Present at 44th Annual Canaccord Growth Conference

Core Insights - Verona Pharma is a biopharmaceutical company focused on developing innovative therapies for chronic respiratory diseases with significant unmet medical needs [1] - The company's first commercial product, OhtuvayreTM (ensifentrine), is the first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule [1] - Ensifentrine has potential applications in various respiratory diseases, including non-cystic fibrosis bronchiectasis, cystic fibrosis, and asthma [1] Company Overview - Verona Pharma plc will present a company overview at the 44th Annual Canaccord Growth Conference on August 13, 2024 [2] - A webcast of the event will be available on the company's website [4]